221 related articles for article (PubMed ID: 12501978)
1. Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.
Shimon I; Nass D; Gross DJ
Pituitary; 2001 Sep; 4(4):265-9. PubMed ID: 12501978
[TBL] [Abstract][Full Text] [Related]
2. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
[TBL] [Abstract][Full Text] [Related]
3. [Excellent response to lanreotide treatment of thyrotropin and prolactin secreting pituitary macroadenoma].
Murillo Sanchís J; Martín AL; Salinas Vert I; Sanmartí Sala A
Med Clin (Barc); 2000 Feb; 114(6):238. PubMed ID: 10757110
[No Abstract] [Full Text] [Related]
4. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
Lucas T; Astorga R; Catalá M;
Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
[TBL] [Abstract][Full Text] [Related]
6. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
8. A challenging TSH/GH co-secreting pituitary adenoma with concomitant thyroid cancer; a case report and literature review.
Yoon JH; Choi W; Park JY; Hong AR; Kim SS; Kim HK; Kang HC
BMC Endocr Disord; 2021 Aug; 21(1):177. PubMed ID: 34461869
[TBL] [Abstract][Full Text] [Related]
9. Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal.
Livadas S; Hadjidakis DJ; Argyropoulou MI; Stamatelatou M; Kelekis D; Raptis SA
Hormones (Athens); 2006; 5(1):57-63. PubMed ID: 16728386
[TBL] [Abstract][Full Text] [Related]
10. The future of somatostatin analogue therapy.
Stewart PM; James RA
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):409-18. PubMed ID: 10909432
[TBL] [Abstract][Full Text] [Related]
11. Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases.
Tokutsu A; Okada Y; Torimoto K; Otsuka T; Narisawa M; Kurozumi A; Tanaka Y
Neuro Endocrinol Lett; 2020 Apr; 41(1):10-16. PubMed ID: 32338854
[TBL] [Abstract][Full Text] [Related]
12. Long term treatment of a thyrotropin-secreting microadenoma with somatostatin analogues.
Prieto-Tenreiro A; Díaz-Guardiola P
Arq Bras Endocrinol Metabol; 2010; 54(5):502-6. PubMed ID: 20694413
[TBL] [Abstract][Full Text] [Related]
13. Lanreotide autogel-induced tumour shrinkage in thyrotropin-secreting pituitary macroadenomas.
Paniagua AE; Bernabeu I; Leskela S; Marazuela M
Clin Endocrinol (Oxf); 2011 Mar; 74(3):406-8. PubMed ID: 21091752
[No Abstract] [Full Text] [Related]
14. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
15. An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant.
Meas T; Sobngwi E; Vexiau P; Boudou P
Ann Endocrinol (Paris); 2006 Jun; 67(3):249-52. PubMed ID: 16840917
[TBL] [Abstract][Full Text] [Related]
16. Silent pituitary macroadenoma co-secreting growth hormone and thyroid stimulating hormone.
Sen O; Ertorer ME; Aydin MV; Erdogan B; Altinors N; Zorludemir S; Guvener N
J Clin Neurosci; 2005 Apr; 12(3):318-20. PubMed ID: 15851094
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
18. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
Shimon I; Nass D; Hadani M
Pituitary; 2000 May; 2(4):289-94. PubMed ID: 11081151
[TBL] [Abstract][Full Text] [Related]
19. Medical management of thyrotropin-secreting pituitary adenomas.
Beck-Peccoz P; Persani L
Pituitary; 2002; 5(2):83-8. PubMed ID: 12675505
[TBL] [Abstract][Full Text] [Related]
20. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
